Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –
Novartis 3. Research & Development FTEs by Year
Novartis 3. Research & Development FTEs: 20,015 in FY2025, up 1.7% from a year earlier.
Latest, FY2025
20,015
Period ended Dec 31, 2025
Change on a year earlier
+1.7%
19,682 in FY2024
History
3 years
Since FY2023
Sources
1
Novartis Form 20-F (0001114448-26-000004)
Where the FY2025 figure comes from
“|| Total | 27 288 | 20 015 | 16 487 | 11 477 | 75 267”
Source: Novartis Form 20-F (0001114448-26-000004) ↗
Reported in Form 20-F Item 6.D.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | 3. Research & Development FTEs | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20,015 | +1.7% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2024 | Dec 31, 2024 | 19,682 | +1.8% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2023 | Dec 31, 2023 | 19,333 | – | Novartis Form 20-F (0001114448-26-000004) ↗ |
Breakdown
What makes up 3. Research & Development FTEs
Cite this data
StockData. (2026). Novartis 3. Research & Development FTEs, annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/wf-fte-rd
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.